Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341884 · ClinicalTrials.gov registry record · Phase 1
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03341884 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 29 participants.
The verdict
NCT03341884, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1 study evaluating the pharmacokinetics, tolerability and safety of a single dose of ipatasertib in participants with mild, moderate or severe hepatic impairment compared to healthy participants.
Interventions
- DRUG Ipatasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-11-09 |
| Est. Completion | 2018-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03341884
The ClinicalTrials.gov registry entry for NCT03341884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipatasertib is the first listed.
NCT03341884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03341884 about?
NCT03341884 is a clinical study titled "A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants". This is a Phase 1 study evaluating the pharmacokinetics, tolerability and safety of a single dose of ipatasertib in participants with mild, moderate or severe hepatic impairment compared to healthy participants.
What is the current status of trial NCT03341884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-11-09. Estimated completion is 2018-06-26.
What interventions are being tested in trial NCT03341884?
The interventions under investigation include: Ipatasertib (DRUG).
Who is sponsoring clinical trial NCT03341884?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.